Cigna, a health insurer, is exploring the potential sale of its Medicare Advantage business, prompting questions from analysts. The company is adopting a strategy similar to that of billionaire Mark Cuban to sell medicines at a set markup. Additionally, there is a trend among incumbent insurers and retailers to launch new models in response to Cost Plus Drugs. The drug-payment system's unique market dynamics have led some drugmakers to set two prices for the same medicine, with health plans opting to cover the more expensive versions.
The drug-payment system doesn’t work like most markets, which is why some drugmakers are setting two prices for the same medicine—and health plans are choosing to cover the more expensive versions https://t.co/DeFXOysY25 https://t.co/DeFXOysY25
Cigna will follow Cost Plus Drug's playbook, offering a cost-plus drug option The trend: incumbent insurers and retailers are starting to launch new models to keep up with Cost Plus Drugs https://t.co/tGGGRGojR9
Cigna is taking a page from billionaire Mark Cuban’s playbook to sell medicines for a set markup https://t.co/fNfL7cL7Rb
Medical News in Brief: In US, Prices for Common Health Services Vary Widely by Location https://t.co/1V54jEyHIi
An analyst has questions about Cigna's potential efforts to sell its Medicare Advantage business, as STAT explores in this week's Health Care Inc. newsletter. https://t.co/t5xSXHfchU